| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q2'26 | $2.25 | - | - |
| Q1'26 | $2.24 | $1.71 | -23.7% |
| Q3'25 | $1.71 | $1.78 | +4.1% |
| Q2'25 | $2.03 | $2.05 | +0.8% |
| Q1'25 | $1.65 | $1.30 | -21.3% |
| Q4'24 | $2.25 | $2.41 | +7.0% |
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q2'26 | $26.3B | - | - |
| Q1'26 | $25.7B | $25.4B | -0.9% |
| Q3'25 | - | $25.3B | - |
| Q2'25 | - | $25.2B | - |
| Q1'25 | - | $23.8B | - |
| Q4'24 | - | $30.9B | - |
Market Data
TGT is currently trading at $139.60, giving Target Corporation a market cap of 63.41B and a P/E ratio of 18.4. Today's range spans $139.36–$143.21, with shares opening at $141.31 and moving up $0.00 (0.0%) from the prior close. DailyIQ's technical score sits at 95/100 (BUY) with a news sentiment reading of 62/100.
Over the past year TGT has traded between $83.44 and $144.40 - the current price is +67.3% off the 52-week low and -3.3% from the high. 45 analysts cover the stock with a Hold consensus and a mean 12-month target of $133.70 (range $92.00–$162.00), implying downside of -4.2%.
Cross-asset context supports the bullish read on TGT: when Consumer Defensive sector conditions are favorable, large-cap names with 95/100 technical scores (BUY) and bullish sentiment (62/100) outperform on a risk-adjusted basis. Price: $139.60 (near 52-week highs). (P/E: 18.4) The 52-week context of $83.44–$144.40 shows the full trading history - and the current setup is one of the stronger entries within that range. At 63.41B in market cap, position sizing is the key variable, not the direction.
What makes TGT's BUY setup (95/100) particularly actionable at 63.41B in Consumer Defensive capitalization is the scale-to-move ratio: large enough to feature on institutional mandates but not so large that the percentage upside is already compressed by index inertia. At $139.60 (near 52-week highs in $83.44–$144.40), with sentiment running bullish at 62/100, the setup rewards conviction-sized positioning more than it does speculative small bets.
Sentiment gathered from recent headlines
Most recent articles, ranked by recency (click to expand).